Last reviewed · How we verify

KL1333 — Competitive Intelligence Brief

KL1333 (KL1333) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mitochondrial permeability transition pore inhibitor. Area: Oncology.

phase 2 Mitochondrial permeability transition pore inhibitor mPTP Oncology Small molecule Live · refreshed every 30 min

Target snapshot

KL1333 (KL1333) — Abliva AB. KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KL1333 TARGET KL1333 Abliva AB phase 2 Mitochondrial permeability transition pore inhibitor mPTP

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mitochondrial permeability transition pore inhibitor class)

  1. Abliva AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KL1333 — Competitive Intelligence Brief. https://druglandscape.com/ci/kl1333. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: